Prospective Observational Long-Term Safety and Effectiveness Registry of Patients Who Have Received Iltamiocel as Part of Cook Myosite, Inc. Sponsored CELLEBRATE Clinical Study in Patients With Persistent or Recurrent Stress Urinary Incontinence (SUI) Following Surgical Treatment
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs Iltamiocel (Primary)
- Indications Stress incontinence
- Focus Adverse reactions; Therapeutic Use
- 26 Dec 2024 New trial record